Evaluation of lithium as an inhibitory agent of herpes simplex virus in cell cultures and during reactivation of latent infection in rabbits.
Lithium carbonate inhibited plaque formation of herpes simplex virus types 1 and 2 in rabbit kidney and Vero cells (50% effective dose, 435.5 to 490 micrograms/ml). Plasma lithium levels of 67 to 134 micrograms/ml were achieved by oral therapy in rabbits. However, neither ocular virus shedding nor virus-positive trigeminal ganglia were reduced after intentional reactivation of latent herpes simplex virus infection.
D000818:Animals; D006561:Herpes Simplex / Q000188:drug therapy*; D007668:Kidney; D008094:Lithium / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D011817:Rabbits; D012008:Recurrence; D018139:Simplexvirus / Q000187:drug effects*; D010948:Viral Plaque Assay; D014776:Virus Cultivation
D008094:Lithium